[1] 全国儿科哮喘协作组. 全国90万0~14岁儿童中支气管哮喘患病情况调查[J]. 中华结核和呼吸杂志, 1993, 16(Z1):64-68.
[2] 全国儿科哮喘协作组, 中国疾病预防控制中心环境与健康相关产品安全所. 第三次中国城市儿童哮喘流行病学调查[J]. 中华儿科杂志, 2013, 51(10):729-735. doi:  10.3760/cma.j.issn.0578-1310.2013.10.003
[3] 全国儿童哮喘防治协作组. 中国城区儿童哮喘患病率调查[J]. 中华儿科杂志, 2003, 41(2):123-127. doi:  10.3760/j.issn:0578-1310.2003.02.014
[4] MOORE W C, BLEECKER E R, CURRAN-EVERETT D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program[J]. J Allergy Clin Immunol,2007,119(2):405-413. doi:  10.1016/j.jaci.2006.11.639
[5] XIANG L, ZHAO J, ZHENG Y J, et al. Uncontrolled asthma and its risk factors in Chinese children: a cross-sectional observational study[J]. J Asthma,2016,53(7):699-706. doi:  10.3109/02770903.2016.1144199
[6] NAVINÉS-FERRER A, SERRANO-CANDELAS E, MOLINA-MOLINA G J, et al. IgE-related chronic diseases and anti-IgE-based treatments[J]. J Immunol Res,2016,2016:8163803.
[7] 虞琳, 张慧珊, 赵欣, 等. 奥马珠单抗治疗儿童中重度变应性哮喘疗效及安全性病例系列研究[J]. 中华实用儿科临床杂志, 2020, 35(8):617-621. doi:  10.3760/cma.j.cn101070-20200330-00529
[8] 钟志娟, 王灵, 冯小伟, 等. 奥马珠单抗对儿童难治性过敏性哮喘伴鼻炎的疗效及其外周血tIgE和EOS计数的影响[J]. 中国免疫学杂志, 2022, 38(4):469-473. doi:  10.3969/j.issn.1000-484X.2022.04.016
[9] 文惯宇, 邓欢, 刘峰, 等. 奥马珠单抗在儿童变应性哮喘并特应性皮炎中的应用[J]. 中华实用儿科临床杂志, 2021, 36(12):957-960. doi:  10.3760/cma.j.cn101070-20201103-01707
[10] 刘玲, 周薇, 李灵慧. 奥马珠单抗治疗儿童过敏性疾病28例临床分析[J]. 中华实用儿科临床杂志, 2021, 36(12):926-930. doi:  10.3760/cma.j.cn101070-20210327-00356
[11] MARCOTTE G. V. Omalizumab therapy for hyper-IgE syndrome[J]. J Allergy Clin Immunol,2008,121(2):S88.
[12] MAQBOOL S, HSIEH F, MCDONNELL J, et al. Safety and efficacy of omalizumab in atopic dermatitis—A preliminary report[J]. J Allergy Clin Immunol,2005,115(2):S106.
[13] 尹悦, 李莉. IgE的新作用[J]. 中国免疫学杂志, 2019, 35(18):2284-2288. doi:  10.3969/j.issn.1000-484X.2019.18.022
[14] 奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3):179-185. doi:  10.3760/cma.j.issn.1001-0939.2018.03.007
[15] CASALE T B, LUSKIN A T, BUSSE W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, A prospective real-world study[J]. J Allergy Clin Immunol Pract,2019,7(1):156-164.e1. doi:  10.1016/j.jaip.2018.04.043
[16] GIUBERGIA V, RAMÍREZ FARÍAS M J, PÉREZ V, et al. Clinical impact of omalizumab treatment in children with severe asthma: report of a local experience[J]. Arch Argent Pediatr,2019,117(2):e115-e120.
[17] 国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组哮喘协作组, 中国医药教育协会儿科专业委员会, 等. 奥马珠单抗在儿童过敏性哮喘临床应用专家共识[J]. 中华实用儿科临床杂志, 2021, 36(12):881-890. doi:  10.3760/cma.j.cn101070-20210531-00621
[18] HANANIA N A, WENZEL S, ROSÉN K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study[J]. Am J Respir Crit Care Med,2013,187(8):804-811. doi:  10.1164/rccm.201208-1414OC
[19] YU C J, WANG K J, CUI X Y, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials[J]. Am J Rhinol Allergy,2020,34(2):196-208. doi:  10.1177/1945892419884774
[20] MACDONALD K M, KAVATI A, ORTIZ B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018[J]. Expert Rev Clin Immunol,2019,15(5):553-569. doi:  10.1080/1744666X.2019.1574571
[21] NIETO GARCÍA A, GARRIGA-BARAUT T, PLAZA MARTÍN A M, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma[J]. Pediatr Allergy Immunol,2021,32(5):980-991. doi:  10.1111/pai.13484
[22] Global Initiative for Asthma. Global strategy for asthma management and prevention main report 2020 [EB/OL]. (2020-03-20) [2021-05-15]. https://ginasthma. org/reports/.
[23] MILGROM H, FOWLER-TAYLOR A, VIDAURRE C F, et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma[J]. Curr Med Res Opin,2011,27(1):163-169. doi:  10.1185/03007995.2010.539502
[24] RODRIGO G J, NEFFEN H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents[J]. Pediatr Allergy Immunol,2015,26(6):551-556. doi:  10.1111/pai.12405
[25] COX L, LIEBERMAN P, WALLACE D, et al. American academy of allergy, asthma & immunology/American college of allergy, asthma & immunology omalizumab-associated anaphylaxis joint task force follow-up report[J]. J Allergy Clin Immunol,2011,128(1):210-212. doi:  10.1016/j.jaci.2011.04.010